The amount of electronic health care data is rapidly growing due to the widespread adoption of electronic health records and the popularity of digital health tools, such as wearable devices, biosensors, apps, and remote patient monitoring.
BPC's new report, Expanding the Use of Real-World Evidence in Regulatory and Value-Based Payment Decision-Making for Drugs and Biologics, offers recommendations for leveraging this data, while protecting patient privacy, to improve the Food and Drug Administration's regulatory decision-making, as well as value-based payment for drugs and biologics. |